Compounds > lonidamine
Page last updated: 2024-08-23

lonidamine and arsenic

lonidamine has been researched along with arsenic in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bruey, JM; Corcos, L; Garrido, C; Leroy, I; Lizard, G; Miguet, C; Plenchette, S; Rébé, C; Solary, E; Sordet, O1
Auffray, C; Candeil, L; Copois, V; Crabbé, L; Del Rio, M; Gourdier, I; Martineau, P; Mechti, N; Pau, B; Pommier, Y; Ychou, M1
Aller, P; Calviño, E; de Blas, E; Sánchez, Y; Simón, GP1
Aller, P; Boyano-Adánez, Mdel C; Bréard, J; Calviño, E; de Blas, E; Estañ, MC; Sancho, P; Simón, GP1
Aller, P; Boyano-Adánez, Mdel C; Calviño, E; Calvo, S; de Blas, E; Estañ, MC; Guillén-Guío, B; Rial, E1

Other Studies

5 other study(ies) available for lonidamine and arsenic

ArticleYear
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis.
    Blood, 2001, Jun-15, Volume: 97, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Cell-Free System; Drug Resistance; Etoposide; Humans; Indazoles; Leukemia; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2; Tetradecanoylphorbol Acetate; U937 Cells

2001
Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma.
    FEBS letters, 2002, Oct-09, Volume: 529, Issue:2-3

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Blotting, Western; Caspase 3; Caspases; Colonic Neoplasms; DNA Primers; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Indazoles; Models, Biological; Organoplatinum Compounds; Oxaliplatin; Oxides; Proto-Oncogene Proteins c-bcl-2

2002
Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 335, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Survival; Curcumin; Electrophoretic Mobility Shift Assay; Flow Cytometry; Glutathione; HL-60 Cells; Humans; Indazoles; Membrane Potentials; Mitochondria; Oxidants; Oxides; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; U937 Cells

2010
Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
    Biochemical pharmacology, 2011, Dec-01, Volume: 82, Issue:11

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Indazoles; Leukemia; Membrane Potential, Mitochondrial; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases

2011
Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Deoxyglucose; Epoxy Compounds; Glycolysis; Humans; Indazoles; Leukemia, Myeloid, Acute; Oxidative Stress; Oxides; Protein Kinases

2014